---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-051485"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:02:19.615348+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GNI Group, controlling shareholder of Gyre Therapeutics, raises FY2023 forecast; revenue +3.9%, op profit +21.5%

## Summary
- FY2023 revenue forecast raised to ¥26,267M (from ¥25,273M); operating profit to ¥7,280M (from ¥5,991M).
- Net profit attributable to parent raised to ¥2,005M; basic EPS revised to ¥42.20 from ¥35.86.
- ETUARY® sales in China exceeded expectations; Cullgen's Astellas alliance revenue above prior forecast.
- Forex assumptions revised: US$1=¥138.24 and RMB1=¥19.62 (from ¥130.77 and ¥19.38).
- Previous 2022 actuals: revenue ¥17,418M, net profit ¥388M, EPS ¥8.19.

## SEC filing metadata
- accession: 0001140361-23-051485
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123051485/0001140361-23-051485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123051485/ny20009756x14_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-051485
- JSON: https://secwatch.observer/filing/0001140361-23-051485.json
- Plain text: https://secwatch.observer/filing/0001140361-23-051485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.